Zobrazeno 1 - 10
of 77
pro vyhledávání: '"U. Rueffer"'
Autor:
Peter Borchmann, Karolin Behringer, Andreas Josting, Volker Diehl, Andreas Engert, Hans Michael Kvasnicka, J. U. Rueffer, Roland Schnell, Juergen Thiele
Publikováno v:
Der Pathologe. 27:47-52
Das maligne Hodgkin-Lymphom (HL) ist durch die fortschreitende Entwicklung der Behandlungsintensitat eine heilbare Erkrankung geworden. Allerdings kann dieses aggressive Vorgehen, das haufig Strahlen- und Chemotherapie kombiniert, u. a. sekundare Neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18e98856d16888dfcc12be267c2c6858
https://doi.org/10.1007/s00292-005-0811-0
https://doi.org/10.1007/s00292-005-0811-0
Autor:
M, Sieber, H, Tesch, B, Pfistner, U, Rueffer, U, Paulus, R, Munker, R, Hermann, G, Doelken, P, Koch, J, Oertel, S, Roller, P, Worst, H, Bischof, A, Glunz, R, Greil, K, von Kalle, K P, Schalk, D, Hasenclever, O, Brosteanu, E, Duehmke, A, Georgii, A, Engert, M, Loeffler, V, Diehl, R P, Mueller, N, Willich, R, Fischer, M L, Hansmann, H, Stein, T, Schober, B, Koch
Publikováno v:
Annals of Oncology. 15:276-282
Background: The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP (cyclophosphamide–vincristine–procarbazine–prednisone–doxorubicin–bleomycin–vinblastine–ifosfamide–methotrexate–e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd36ca50b3a44a1c38dfc4c148f4d8ab
https://doi.org/10.1093/annonc/mdh046
https://doi.org/10.1093/annonc/mdh046
Autor:
E. Duehmke, Peter Koch, Richard Greil, Jeremy Franklin, M. Sieber, Jürgen Wolf, Markus Loeffler, Dirk Hasenclever, Andreas Engert, Axel Georgii, Anselmo Ap, Andreas Josting, Michael Pfreundschuh, Beate Pfistner, Reinhold Munker, Hans Tesch, Volker Diehl, Gottfried Doelken, B. Lathan, Klaus-Peter Schalk, Richard Herrmann, Hartmut Kirchner, Oana Brosteanu, Ursula Paulus, U. Rueffer, T. Koch
Publikováno v:
Journal of Clinical Oncology. 20:476-484
PURPOSE: To investigate whether treatment results in intermediate-stage Hodgkin’s lymphoma can be improved by rapid application of non–cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba032bbf0313e57c998d684bcf7fe470
https://doi.org/10.1200/jco.2002.20.2.476
https://doi.org/10.1200/jco.2002.20.2.476
Publikováno v:
Zeitschrift für Palliativmedizin. 15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d5e497036e46031ef27dfd6f4ed94b0
https://doi.org/10.1055/s-0034-1374217
https://doi.org/10.1055/s-0034-1374217
Autor:
Kai Breuer, Juergen Wolf, Andreas Engert, H. Nisters-Backes, Oliver Manzke, U. Rueffer, Hans Tesch, Volker Diehl, Henning Bredenfeld, F. J. Grotenhermen, B. Lathan, Andreas Josting, M. Sieber, Peter Koch
Publikováno v:
Annals of Oncology. 12:1307-1311
UNLABELLED Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens. To investigate whether gonadal failure is related primarily to the toxic effect of che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e2f6a749b5ffd2259d1cb5a874d554
https://doi.org/10.1023/a:1012464703805
https://doi.org/10.1023/a:1012464703805
Autor:
Peter Koch, M Sextro, D. Hasenclever, Jeremy Franklin, Michael Pfreundschuh, H. Kirchner, B. Lathan, Hans Tesch, U. Rueffer, Volker Diehl, G. Ehninger, N. Schmitz, M. Loeffler
Publikováno v:
Annals of Oncology. 12:471-477
Summary Background The magnitude of chemotherapy dose escalation made possible by the use of recombinant haematopoietic growth factors has not been quantified in a randomized trial Patients and methods Patients with refractory or relapsing Hodgkin’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4546e9b95a48a879aea192c6375ce0c9
https://doi.org/10.1023/a:1011108722666
https://doi.org/10.1023/a:1011108722666
Publikováno v:
Scopus-Elsevier
To determine prognostic factors and treatment outcome, patients with primary progressive Hodgkin lymphoma (HD) registered in the database of the German Hodgkin Lymphoma Study Group (GHSG) were analyzed retrospectively. Detailed records from randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2799e74656f6db9c5879b82516e60247
https://doi.org/10.1182/blood.v96.4.1280.h8001280_1280_1286
https://doi.org/10.1182/blood.v96.4.1280.h8001280_1280_1286
Autor:
Juergen Wolf, Marcel Reiser, U. Rueffer, Hans Tesch, PD Wickramanayake, Andreas Josting, Diehl, D. Söhngen, Andreas Engert, Andreas Draube
Publikováno v:
Leukemia & Lymphoma. 37:115-123
We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7836188c966e0dd487e82d3cb1a4c1
https://doi.org/10.3109/10428190009057634
https://doi.org/10.3109/10428190009057634
Autor:
Peter Koch, Rainer Haas, U. Rueffer, Michael Pfreundschuh, Oana Brosteanu, R Kuse, Norbert Schmitz, D. Hasenclever, B. Lathan, Hartmut Kirchner
Publikováno v:
Journal of Clinical Oncology. 12:580-586
PURPOSE A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage chemotherapy for patients with Hodgkin's disease. PATIENTS AND METHODS Fifty-five pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e53aa2c83299eba6b4f553f32acec1d
https://doi.org/10.1200/jco.1994.12.3.580
https://doi.org/10.1200/jco.1994.12.3.580
Autor:
P, Borchmann, K, Behringer, A, Josting, J U, Rueffer, R, Schnell, V, Diehl, A, Engert, H M, Kvasnicka, J, Thiele
Publikováno v:
Der Pathologe. 27(1)
Malignant Hodgkin's lymphoma (HL) has become a curable disease through the increasing intensity of the treatment strategies applied. These regimens are aggressive, including radiotherapy and chemotherapy leading to the possibility of secondary malign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd927cd282538f45f55efcd9fffd4242
https://pubmed.ncbi.nlm.nih.gov/16369761
https://pubmed.ncbi.nlm.nih.gov/16369761